Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

Br J Haematol. 2000 Oct;111(1):277-9. doi: 10.1046/j.1365-2141.2000.02402.x.

Abstract

The anti-CD33 monoclonal antibody linked to NAc-gamma calicheamicin gemtuzumab ozogamicin (CMA-676) was used to treat a patient with Philadelphia/bcr-abl-positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real-time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3-log tumour mass reduction in bone marrow.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Aminoglycosides*
  • Anti-Bacterial Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bone Marrow / pathology
  • Cytogenetic Analysis
  • Female
  • Fusion Proteins, bcr-abl
  • Gemtuzumab
  • Humans
  • Immunotoxins / therapeutic use*
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / pathology
  • Leukemia, Myeloid / therapy*
  • Middle Aged
  • Philadelphia Chromosome
  • Polymerase Chain Reaction
  • Remission Induction

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunotoxins
  • Gemtuzumab
  • Fusion Proteins, bcr-abl